Cabozantinib and Panitumumab for RAS Wild‐Type Metastatic Colorectal Cancer

LESSONS LEARNED: Antitumor activity was observed in the study population. Dose modifications of cabozantinib improve long‐term tolerability. Biomarkers are needed to identify patient populations most likely to benefit. Further study of cabozantinib with or without panitumumab in patients with metast...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Strickler, John H., Rushing, Christel N., Uronis, Hope E., Morse, Michael A., Niedzwiecki, Donna, Blobe, Gerard C., Moyer, Ashley N., Bolch, Emily, Webb, Renee, Haley, Sherri, Hatch, Ace J., Altomare, Ivy P., Sherrill, Gary B., Chang, David Z., Wells, James L., Hsu, S. David, Jia, Jingquan, Zafar, S. Yousuf, Nixon, Andrew B., Hurwitz, Herbert I.
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2021
主題:
Clinical Trial Results
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176979/
https://ncbi.nlm.nih.gov/pubmed/33469991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13678
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料